OptiBiotix Health PLC Presentation of data at European Microbiome Summit
03 November 2016 - 6:01PM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
03 November 2016
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Presentation of research data at European Microbiome Summit
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces that it is presenting at the European
Edition of the Microbiome Summit 2016 in London. The conference
will be held at the Holiday Inn in Kensington on the 3(rd) and
4(th) November. This is the only conference in Europe dedicated
specifically to the microbiome and its development.
The human microbiome has been acknowledged to have significant
impact, not only in disease but more importantly in health and
wellbeing. Major advances in next generation sequencing
technologies have enabled scientific research in connecting an
imbalanced microbiome to conditions as diverse as cancer,
pulmonary, metabolic, inflammatory and mental/neurodegenerative
disease.
The conference is credited for attracting leading research
scientists, leading companies in the industry and well connected
investment groups, and is a good opportunity to network with
like-minded individuals.
The presentation, by Stephen O'Hara, will take place on Friday
4(th) November and is entitled "Targeted Microbiome Modulation:
Next Generation Pre-, Pro-, and Syn-biotics".
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876
741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGMMGMVZVGVZM
(END) Dow Jones Newswires
November 03, 2016 03:01 ET (07:01 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024